Jin M, et al. - Given that inadequate adherence to sublingual immunotherapy (SLIT) has become a major cause of unsatisfactory clinical effectiveness for patients with allergic rhinitis (AR), researchers identified the impact of different first prescription lengths on the adherence to SLIT. Clinical data of 306 AR patients who began SLIT between January 2017 and June 2018 were reviewed retrospectively. Study participants were divided into three groups according to the length of their first prescription (group A: less than 3 months, group B: 3 to 6 months, group C: more than 6 months).  Groups A, B, and C involved 102, 161, and 43 individuals, respectively. Data reported that the average lengths of the first prescription for group A, B, and C, respectively, were 62.52 ± 17.63, 102.21 ± 9.22, and 189.07 ± 17.97 days. A significance differences were found among the 3 groups. Six months is recommended in some circumstances as the standard length for the first prescription which can significantly improve adherence to SLIT in AR patients.